Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of NeurologyGlobeNewsWire • 04/18/24
Tiziana Life Sciences to present new imaging data for lead asset at upcoming neurology conferenceProactive Investors • 04/11/24
Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of NeurologyGlobeNewsWire • 04/11/24
Tiziana Life Sciences to present positive data for lead drug candidate in Alzheimer's diseaseProactive Investors • 03/05/24
Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer's DiseaseGlobeNewsWire • 03/05/24
Tiziana Life Sciences reveals positive clinical, PET scan findings for intranasal Foralumab in MS patientsProactive Investors • 01/08/24
Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis PatientsGlobeNewsWire • 01/08/24
Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024GlobeNewsWire • 01/05/24
Tiziana Life Sciences files patent for foralumab combination therapy for obesity-associated inflammationProactive Investors • 01/05/24
Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated InflammationGlobeNewsWire • 01/05/24
Tiziana Life Sciences doses first patient in mid-stage multiple sclerosis studyProactive Investors • 12/19/23
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple SclerosisGlobeNewsWire • 12/19/23
Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment WebinarGlobeNewsWire • 12/04/23
Tiziana Life Sciences advances multiple sclerosis research program with enrollment and dosing of patientsProactive Investors • 11/30/23
Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple SclerosisGlobeNewsWire • 11/30/23
Tiziana Life Sciences to Present Recent Clinical Updates at BIO-Europe in Munich, Germany, November 6-8, 2023GlobeNewsWire • 11/01/23
Tiziana Life Sciences: FDA signs off on home-based protocol fo MS treatmentProactive Investors • 10/18/23
Tiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis TreatmentGlobeNewsWire • 10/18/23
Tiziana Life Sciences stock continues to climb; COO ‘excited' by recent resultsProactive Investors • 10/16/23
Tiziana Life Sciences reveals positive clinical results for MS patients treated with ForalumabProactive Investors • 10/16/23
Tiziana Life Sciences Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal ForalumabGlobeNewsWire • 10/16/23
Tiziana Life Sciences' Matthew Davis discusses significance of latest MS treatment dataProactive Investors • 10/16/23
Tiziana Life Sciences reveals positive PET scan results with Foralumab to treat MS patientsProactive Investors • 10/13/23
Tiziana Announces Positive Qualitative Six-Month PET Scan Results With Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed With Non-Active Secondary Progressive MS (na-SPMS)GlobeNewsWire • 10/13/23
Tiziana Life Sciences to present MS treatment at ECTRIMS Annual CongressProactive Investors • 10/11/23